Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.45 |
| ▸ | CDK7 | P50613 | 3/20 | 0.38 |
| ▸ | CCNH | P51946 | 3/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | ITK | Q08881 | 4/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | CDK14 | O94921 | 1/20 | 0.36 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481527 | 0.83 | BTK (0.40) | BTKCDK7CCNHPLCG1EGFR | |
| SCHEMBL15938439 | 0.69 | HDAC3 (0.55) | BTK | |
| SCHEMBL15938442 | 0.69 | HDAC3 (0.55) | BTK | |
| SCHEMBL20206274 | 0.68 | MMP1 (0.57) | BTKEGFRITKJAK3LYN | |
| SCHEMBL16653925 | 0.67 | KDM4E (0.61) | BTK | |
| SCHEMBL16653927 | 0.67 | KDM4E (0.61) | BTK | |
| SCHEMBL17931890 | 0.66 | BTK (0.53) | BTKEGFRITKJAK3LYN | |
| SCHEMBL27462537 | 0.65 | BTK (0.48) | BTKEGFRITKJAK3CDK14 | |
| SCHEMBL21484259 | 0.63 | NPC1 (0.49) | — | |
| SCHEMBL13389249 | 0.63 | EGFR (0.55) | BTKCDK7CCNHMNAT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2019197546-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | BTK 528/4885CDK7 10/4885CCNH 56/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | BTK 2208/4885CDK7 159/4885CCNH 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.